Megan Othus

Dr. Megan Othus

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MOMegan Othus
Megan Othus
BBBart Barlogie
Bart Barlogie
MLMichael L. LeBlanc
Michael L. LeBlanc
JCJohn J. Crowley
John J. Crowley
Cure models are a popular topic within statistical literature but are not as widely known in the clinical literature. Many patients with cancer can be long-term survivors of their disease, and cure models can be a useful tool to analyze and describe cancer survival data. The goal of this article is to review what a cure model is, explain when cure models can be used, and use cure models to describe multiple myeloma survival trends. Multiple myeloma is generally considered an incurable disease, and this article shows that by using cure models, rather than the standard Cox proportional hazards model, we can evaluate whether there is evidence that therapies at the University of Arkansas for Medical Sciences induce a proportion of patients to be long-term survivors. Clin Cancer Res; 18(14); 3731–6. ©2012 AACR.

13 June 2013 in Leukemia
Verified
Journal Article
Open access
PDF file
MOMegan Othus
Megan Othus
HKH Kantarjian
H Kantarjian
SPS Petersdorf
S Petersdorf
FRF Ravandi
F Ravandi
JGJ Godwin
J Godwin
EEE Estey
E Estey
Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15–20% observed 20 years ago. Herein we test this assumption. We examined TRM rates in 1409 patients treated on SWOG (Southwest Oncology Group) trials and 1942 patients treated at MD Anderson (MDA) from 1991 to 2009. Eighty-eight percent of SWOG patients received ‘3+7’ or regimens of similar intensity while 92% of the MDA patients received ara-C at 1.5–2.0 g/m2 daily × 3–5 days+other cytotoxic agents. We examined the relationship between time and TRM rates after accounting for other covariates. TRM rates between 1991 and 2009 decreased from 18–3% in SWOG and 16–4% at MDA. Multivariate analyses showed a significant decrease in TRM over time (P=0.001). The decrease in TRM was not limited to younger patients, those with a better performance status or a lower white blood cell count. Though our observations are limited to patients treated with intensive therapy at SWOG institutions and MDA, the decrease in TRM with time emphasizes the problem with historical controls and could be considered when selecting AML induction therapy.

1 October 2021 in Cancer Cell
Verified
Journal Article
Open access
YWYujue Wang
Yujue Wang
SLSixue Liu
Sixue Liu
ZYZhentao Yang
Zhentao Yang
AAAlain P. Algazi
Alain P. Algazi
SLShirley H. Lomeli
Shirley H. Lomeli
RLRoger S. Lo
Roger S. Lo
Rationally sequencing and combining PD-1/L1-and MAPK-targeted therapies may overcome innate and acquired resistance. Since increased clinical benefit of MAPK inhibitors (MAPKi) is associated with previous immune checkpoint therapy, we compare the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C. Anti-PD-1/L1 lead-in preceding MAPKi combination optimizes response durability by promoting pro-inflammatory polarization of macrophages and clonal expansion of interferon-γhi, and CD8+ cytotoxic and proliferative (versus CD4+ regulatory) T cells that highly express activation genes. Since therapeutic resistance of melanoma brain metastasis (MBM) limits patient survival, we demonstrate that sequencing anti-PD-1/L1 therapy before MAPKi combination suppresses MBM and improves mouse survival with robust T cell clonal expansion in both intracranial and extracranial metastatic sites. We propose clinically testing brief anti-PD-1/L1 (± anti-CTLA-4) dosing before MAPKi co-treatment to suppress therapeutic resistance.

14 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AAAnjali Advani
Anjali Advani
AMAnna Moseley
Anna Moseley
KOKristen M. O'Dwyer
Kristen M. O'Dwyer
BWBrent L. Wood
Brent L. Wood
MFMin Fang
Min Fang
HEHarry P. Erba
Harry P. Erba
PURPOSE: Chemotherapy outcomes in older patients with Philadelphia (Ph) chromosome–negative B-acute lymphoblastic leukemia (ALL) are very poor. Here, we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristine, 6-mercaptopurine, and methotrexate (POMP) maintenance chemotherapy in this patient population. PATIENTS AND METHODS: Patients were treated at National Clinical Trial Network sites. Eligibility criteria included age ≥ 65 years and newly diagnosed Ph chromosome–negative B-ALL. Patients received blinatumomab as induction for one-two cycles until attainment of response (complete remission (CR) and CR with incomplete count recovery). Patients then received three cycles of consolidation with blinatumomab followed by 18 months of POMP maintenance chemotherapy. Eight doses of intrathecal methotrexate were administered as central nervous system prophylaxis. RESULTS: Twenty-nine eligible patients were enrolled. The median age was 75 years, and the median bone marrow blast count at diagnosis was 87%. Cytogenetic risk was poor in 10 patients (34%), and five of 14 patients (36%) tested had the Ph-like ALL gene signature. Nineteen patients (66%; 95% CI, 46 to 82) achieved CR. Kaplan-Meier 3-year disease-free survival and overall survival estimates were 37% (95% CI, 17 to 57) and 37% (95% CI, 20 to 55), respectively. CONCLUSION: Blinatumomab was well tolerated and effective in the treatment of older patients with newly diagnosed Ph chromosome–negative B-ALL, including patients with poor-risk cytogenetics. The 3-year disease-free survival and overall survival results are encouraging and suggest that this approach should be further explored.

5 October 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AAAlain P. Algazi
Alain P. Algazi
MOMegan Othus
Megan Othus
ADAdil I. Daud
Adil I. Daud
RLRoger S. Lo
Roger S. Lo
JMJanice M. Mehnert
Janice M. Mehnert
ARAntoni Ribas
Antoni Ribas

1 April 2017 in Value in Health
Verified
Journal Article
Closed access
MOMegan Othus
Megan Othus
ABAasthaa Bansal
Aasthaa Bansal
LKLisel Koepl
Lisel Koepl
SWSamuel Wagner
Samuel Wagner
SRScott Ramsey
Scott Ramsey